NCT01988324

AR and ER Imaging in Metastatic Breast Cancer

Androgen Receptor and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University Medical Center Groningen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Knowledge of breast cancer estrogen receptor (ER) expression is of major importance in treatment-decision making. Patients with ER-positive tumors can be treated with anti-oestrogen therapy, which has relatively few side effects compared to chemotherapy. Whole-body tumor ER-expression can be visualized by 18F-fluoroestradiol PET imaging (FES-PET). In addition to ER, the androgen receptor (AR) is a potential new target in breast cancer. PET imaging with 18F-fluorodihydrotestosterone (18F-FDHT) may allow visualization of tumor AR-expression. In the current study we will perform FES-PET and FDHT-PET in metastatic breast cancer patients and evaluate the concordance with concurrent biopsies. Molecular imaging of tumor AR- and ER-expression may well be of value for future treatment decision-making.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
OTHER	FDHT-PET scan
OTHER	FES-PET scan
OTHER	CT-scan
OTHER	Bone scintigraphy
OTHER	Tumor biopsy

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2013-11-20
• Last updated: 2024-05-06

Locations

2 sites across 1 country: Netherlands